CalciMedica — Third Quarter 2026 Earnings Summary

CalciMedica reported a net loss of $1.7 million for the third quarter ended September 30, 2026, with cash, cash equivalents, and short-term investments totaling $13.8 million. The company anticipates its current cash runway will fund operations into the second half of 2027. Clinical updates include plans for an Auxora Phase 1b proof-of-concept trial in pulmonary hypertension and an IND submission for the oral candidate CM5480, both expected in mid-2027. Additionally, the FDA has aligned with CalciMedica's Phase 2b trial design for Auxora in acute pancreatitis, which will utilize lactate dehydrogenase levels for patient enrichment.